Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study

被引:9
作者
Christen, Tim [1 ]
Trompet, Stella [2 ]
Noordam, Raymond [2 ]
Blauw, Lisanne L. [1 ,3 ]
Gast, Karin B. [1 ]
Rensen, Patrick C. N. [3 ,4 ]
van Dijk, Ko Willems [3 ,4 ,5 ]
Rosendaal, Frits R. [1 ]
de Mutsert, Renee [1 ]
Jukema, Wouter [6 ]
机构
[1] LUMC, Dept Clin Epidemiol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] LUMC, Sect Gerontol & Geriatr, Dept Internal Med, Leiden, Netherlands
[3] LUMC, Dept Med, Div Endocrinol, Leiden, Netherlands
[4] LUMC, Einthoven Lab Expt Vasc Med, Leiden, Netherlands
[5] LUMC, Dept Human Genet, Leiden, Netherlands
[6] LUMC, Dept Cardiol, Leiden, Netherlands
关键词
Reverse cholesterol transport; Atherosclerosis; Mendelian randomization; Cohort; Epidemiology; CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; GENOME-WIDE ASSOCIATION; INTIMA-MEDIA THICKNESS; HEART-DISEASE; GENETIC-VARIATION; HDL CHOLESTEROL; HIGH-RISK; CETP; WOMEN;
D O I
10.1016/j.jacl.2017.10.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Several trials to prevent cardiovascular disease by inhibiting cholesteryl ester transfer protein (CETP) have failed, except Randomized EValuation of the Effects of Anacetrapib through Lipid-modification. Thus far, it is unclear to what extent CETP is causally related to measures of atherosclerosis. OBJECTIVE: The aim of the article was to study the causal relationship between genetically determined CETP concentration and carotid intima-media thickness (cIMT) in a population-based cohort study. METHODS: In the Netherlands Epidemiology of Obesity study, participants were genotyped, and cIMT was measured by ultrasonography. We examined the relation between a weighted genetic risk score for CETP concentration, based on 3 single-nucleotide polymorphisms that have previously been shown to largely determine CETP concentration and cIMT using Mendelian randomization in the total population and in strata by sex, Framingham 10-year risk, (pre)diabetes, high-density lipoprotein cholesterol, triglycerides, and statin use. RESULTS: We analyzed 5655 participants (56% women) with a mean age of 56 (range 44 66) years, body mass index of 26 (range 17-61) kg/m(2), and serum CETP of 2.47 (range 0.68-5.33) mu g/mL. There was no evidence for a causal relation between genetically determined CETP and cIMT in the total population, but associations were differently directed in men (16 mu m per mu g/mL increase in genetically determined CETP; 95% confidence interval: -8, 39) and women (-8 mu m; -25, 9). Genetically determined CETP appeared to be associated with cIMT in normoglycemic men (26 mu m; 1, 52) and in (pre)diabetic women (48 mu m; 2, 98). CONCLUSION: In this population-based study, there was no causal relation between genetically determined CETP concentration and cIMT in the total population although we observed directionally differing effects in men and women. Stratified results suggested associations in individuals with different cardiometabolic risk factor profiles, which require replication. (C) 2017 National Lipid Association. All rights reserved.
引用
收藏
页码:137 / 144
页数:8
相关论文
共 44 条
  • [1] Elevated cholesteryl ester transfer protein concentration is associated with an increased risk for cardiovascular disease in women, but not in men, with Type 2 diabetes: the Hoorn Study
    Alssema, M.
    Dekker, J. M.
    Kuivenhoven, J. A.
    Nijpels, G.
    Teerlink, T.
    Scheffer, P. G.
    Diamant, M.
    Stehouwer, C. D. A.
    Bouter, L. M.
    Heine, R. J.
    [J]. DIABETIC MEDICINE, 2007, 24 (02) : 117 - 123
  • [2] An integrated map of genetic variation from 1,092 human genomes
    Altshuler, David M.
    Durbin, Richard M.
    Abecasis, Goncalo R.
    Bentley, David R.
    Chakravarti, Aravinda
    Clark, Andrew G.
    Donnelly, Peter
    Eichler, Evan E.
    Flicek, Paul
    Gabriel, Stacey B.
    Gibbs, Richard A.
    Green, Eric D.
    Hurles, Matthew E.
    Knoppers, Bartha M.
    Korbel, Jan O.
    Lander, Eric S.
    Lee, Charles
    Lehrach, Hans
    Mardis, Elaine R.
    Marth, Gabor T.
    McVean, Gil A.
    Nickerson, Deborah A.
    Schmidt, Jeanette P.
    Sherry, Stephen T.
    Wang, Jun
    Wilson, Richard K.
    Gibbs, Richard A.
    Dinh, Huyen
    Kovar, Christie
    Lee, Sandra
    Lewis, Lora
    Muzny, Donna
    Reid, Jeff
    Wang, Min
    Wang, Jun
    Fang, Xiaodong
    Guo, Xiaosen
    Jian, Min
    Jiang, Hui
    Jin, Xin
    Li, Guoqing
    Li, Jingxiang
    Li, Yingrui
    Li, Zhuo
    Liu, Xiao
    Lu, Yao
    Ma, Xuedi
    Su, Zhe
    Tai, Shuaishuai
    Tang, Meifang
    [J]. NATURE, 2012, 491 (7422) : 56 - 65
  • [3] [Anonymous], 2017, N ENGL J MED
  • [4] Effects of torcetrapib in patients at high risk for coronary events
    Barter, Philip J.
    Caulfield, Mark
    Eriksson, Mats
    Grundy, Scott M.
    Kastelein, John J. P.
    Komajda, Michel
    Lopez-Sendon, Jose
    Mosca, Lori
    Tardif, Jean-Claude
    Waters, David D.
    Shear, Charles L.
    Revkin, James H.
    Buhr, Kevin A.
    Fisher, Marian R.
    Tall, Alan R.
    Brewer, Bryan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
  • [5] Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead-Pro
    Barter, Philip J.
    Rye, Kerry-Anne
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (03) : 439 - 441
  • [6] Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women - The prospective EPIC (European Prospective Investigation into Cancer and Nutrition) - Norfolk population study
    Boekholdt, SM
    Kuivenhoven, JA
    Wareham, NJ
    Peters, RJG
    Jukema, JW
    Luben, R
    Bingham, SA
    Day, NE
    Kastelein, JJP
    Khaw, KT
    [J]. CIRCULATION, 2004, 110 (11) : 1418 - 1423
  • [7] Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease
    Boekholdt, SM
    Thompson, JF
    [J]. JOURNAL OF LIPID RESEARCH, 2003, 44 (06) : 1080 - 1093
  • [8] Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure
    Cao, Guoqing
    Beyer, Thomas P.
    Zhang, Youyan
    Schmidt, Robert J.
    Chen, Yan Q.
    Cockerham, Sandra L.
    Zimmerman, Karen M.
    Karathanasis, Sotirios K.
    Cannady, Ellen A.
    Fields, Todd
    Mantlo, Nathan B.
    [J]. JOURNAL OF LIPID RESEARCH, 2011, 52 (12) : 2169 - 2176
  • [9] Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action
    Clark, RW
    Ruggeri, RB
    Cunningham, D
    Bamberger, MJ
    [J]. JOURNAL OF LIPID RESEARCH, 2006, 47 (03) : 537 - 552
  • [10] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497